1
|
Breton C, Gusdorf L, Durlach A, Viguier M. Occurrence of O'Brien-type annular elastolytic giant cell granuloma during pravastatin treatment illustrating statin-induced photosensitivity. Ann Dermatol Venereol 2023; 150:232-234. [PMID: 37100679 DOI: 10.1016/j.annder.2023.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Revised: 10/30/2022] [Accepted: 03/07/2023] [Indexed: 04/28/2023]
Affiliation(s)
- C Breton
- Dermatology Department, CHU, 51092 Reims Cedex, France
| | - L Gusdorf
- Dermatology Department, CHU, 51092 Reims Cedex, France
| | - A Durlach
- Pathology Department, CHU, 51092 Reims Cedex, France
| | - M Viguier
- Dermatology Department, CHU, 51092 Reims Cedex, France.
| |
Collapse
|
2
|
Marchal V, Souchon PF, Bednarek N, De Aquino A, Landais E, Doco-Fenzy M, Viguier M, Gusdorf L. Early childhood-onset cutaneous xanthomatosis revealing familial hypercholesterolemia. Ann Dermatol Venereol 2023; 150:238-240. [PMID: 37088684 DOI: 10.1016/j.annder.2023.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Revised: 10/23/2022] [Accepted: 02/21/2023] [Indexed: 04/25/2023]
Affiliation(s)
- V Marchal
- Department of Dermatology, Reims University Hospital, Reims, France.
| | - P-F Souchon
- Department of Pediatrics, Reims University Hospital, Reims, France
| | - N Bednarek
- Department of Pediatrics, Reims University Hospital, Reims, France
| | - A De Aquino
- Department of Cardiology, Reims University Hospital, Reims, France
| | - E Landais
- Department of Genetics and EA3801 SFR CAP Santé, Reims University Hospital, Reims, France
| | - M Doco-Fenzy
- Department of Genetics and EA3801 SFR CAP Santé, Reims University Hospital, Reims, France
| | - M Viguier
- Department of Dermatology, Reims University Hospital, Reims, France
| | - L Gusdorf
- Department of Dermatology, Reims University Hospital, Reims, France
| |
Collapse
|
3
|
Arlegui H, Mahé E, Richard MA, De Rycke Y, Viguier M, Beylot-Barry M, Dupuy A, Beneton N, Joly P, Jullien D, Bachelez H, Sbidian É, Chosidow O, Paul C, Tubach F. Impact of the first wave of the COVID-19 pandemic on the treatment of psoriasis with systemic therapies in France: Results from the PSOBIOTEQ cohort. Ann Dermatol Venereol 2023:S0151-9638(23)00009-1. [PMID: 36914553 PMCID: PMC9928748 DOI: 10.1016/j.annder.2023.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Revised: 11/18/2022] [Accepted: 01/31/2023] [Indexed: 02/17/2023]
Abstract
BACKGROUND The nature of the COVID-19 pandemic led to concerns among patients and physicians about the potential impact of immunosuppressive treatments for chronic diseases such as psoriasis on the risk of severe COVID-19. OBJECTIVES To describe treatment modifications and determine the incidence of COVID-19 infection among psoriasis patients during the first wave of the pandemic, and identify the factors associated with these events. METHODS Data from PSOBIOTEQ cohort relating to the first COVID-19 wave in France (March to June, 2020), as well as a patient-centred COVID-19 questionnaire, were used to evaluate the impact of lockdown on changes (discontinuations, delays or reductions) in systemic therapies, and to determine the incidence of COVID-19 cases among these patients. Logistic regression models were used to assess associated factors. RESULTS Among the 1751 respondents (89.3%), 282 patients (16.9%) changed their systemic treatment for psoriasis, with 46.0% of these changes being initiated by the patients themselves. Patients were more likely to experience psoriasis flare-ups during the first wave if they changed their treatment during this period (58.7% vs 14.4%; P < 0.0001). Changes to systemic therapies were less frequent among patients with cardiovascular diseases (P < 0.001), and those aged ≥ 65 years (P = 0.02). Overall, 45 patients (2.9%) reported having COVID-19, and eight (17.8%) required hospitalization. Risk factors for COVID-19 infection were close contact with a positive case (P < 0.001) and living in a region with a high incidence of COVID-19 (P < 0.001). Factors associated with a lower risk of COVID-19 were avoiding seeing a physician (P = 0.002), systematically wearing a mask during outings (P = 0.011) and being a current smoker (P = 0.046). CONCLUSIONS Discontinuation of systemic psoriasis treatments during the first COVID-19 wave (16.9%) - mainly decided by patients themselves (46.0%) - was associated with a higher incidence of disease flares (58.7% vs 14.4%). This observation and factors associated with a higher risk of COVID-19 highlight the need to maintain and adapt patient-physician communication during health crises according to patient profiles, with the aim of avoiding unnecessary treatment discontinuations and ensuring that patients are informed about the risk of infection and the importance of complying with hygiene rules.
Collapse
Affiliation(s)
- H Arlegui
- AP-HP, Hôpital Pitié-Salpêtrière, Centre de Pharmaco-épidémiologie (Cephépi), INSERM, CIC-1901, Paris, France
| | - E Mahé
- Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France
| | - M-A Richard
- Service de Dermatologie, EA 3279: CEReSS - Health Service Research and Quality of Life Centre, Timone Hospital, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, Marseille, France
| | - Y De Rycke
- Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Pharmaco-épidémiologie (Cephépi), CIC-1901, 75013 Paris, France
| | - M Viguier
- Service de Dermatologie-Vénéréologie, Hôpital Robert Debré, Université Reims Champagne Ardenne, 51100 Reims, France
| | - M Beylot-Barry
- Service de Dermatologie, CHU de Bordeaux, Translational Research on Oncodermatology and Rare skin diseases, Bordeaux Institute of Oncology, UMR 1312 INSERM, Université Bordeaux, Bordeaux, France
| | - A Dupuy
- France Univ Rennes, CHU Rennes, 35000 Rennes, France
| | - N Beneton
- REPERES Pharmaco-Epidemiology and Health Services Research, University Rennes and French School of Public Health, Rennes, France
| | - P Joly
- Service de Dermatologie, Hôpital du Mans, Le Mans, France
| | - D Jullien
- Service de Dermatologie, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon F-69003; Lyon-1 University; INSERM U1111 - CIRI, Lyon F-69007, France
| | - H Bachelez
- Service de Dermatologie, Assistance Publique- Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Cité, Paris, France; INSERM UMR1163, Institut Imagine, Paris, France
| | - É Sbidian
- Service de Dermatologie, Assistance Publique- Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Cité, Paris, France; Hôpital Henri Mondor, Clinical Investigation Centre, Université Paris-Est Créteil (UPEC), Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) - EA 7379, Créteil, France
| | - O Chosidow
- Service de Dermatologie, Assistance Publique- Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Cité, Paris, France; Groupe de recherche Dynamyc, EA7380, Faculté de Santé de Créteil, École nationale vétérinaire d'Alfort, USC ANSES, Université Paris-Est Créteil, Créteil, France
| | - C Paul
- Service de Dermatologie, Toulouse University Hospital (CHU), Paul Sabatier University, Toulouse, France
| | - F Tubach
- Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Pharmaco-épidémiologie (Cephépi), CIC-1901, 75013 Paris, France.
| | | |
Collapse
|
4
|
Aleissa M, Viguier M, Khettab H, Assan F, Akroun F, Mallat Z, Tedgui A, Boutouyrie P, Bachelez H. 117 Longitudinal follow-up study of arterial structure in patients with severe psoriasis and treated with ustekinumab or with tumor necrosis factor alpha inhibitors. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
5
|
Curmin R, Guillo S, De Rycke Y, Bachelez H, Beylot‐Barry M, Beneton N, Chosidow O, Dupuy A, Joly P, Jullien D, Richard M, Viguier M, Sbidian E, Paul C, Mahé E, Tubach F. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ. J Eur Acad Dermatol Venereol 2022; 36:2101-2112. [PMID: 35793473 PMCID: PMC9796114 DOI: 10.1111/jdv.18409] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Accepted: 05/18/2022] [Indexed: 01/01/2023]
Abstract
BACKGROUND Biologics are the cornerstone of treatment of patients with moderate-to-severe plaque psoriasis and switches between biologics are frequently needed to maintain clinical improvement over time. OBJECTIVES The main purpose of this study was to describe precisely switches between biologics and how their pattern changed over time with the recent availability of new biologic agents. METHODS We included patients receiving a first biologic agent in the Psobioteq multicenter cohort of adults with moderate-to-severe psoriasis receiving systemic treatment. We described switches between biologics with chronograms, Sankey and Sunburst diagrams, assessed cumulative incidence of first switch by competing risks survival analysis and reasons for switching. We assessed the factors associated with the type of switch (intra-class - i.e. within the same therapeutic class - vs. inter-class) in patients switching from a TNF-alpha inhibitor using multivariate logistic regression. RESULTS A total of 2153 patients was included. The cumulative incidence of switches from first biologic was 34% at 3 years. Adalimumab and ustekinumab were the most prescribed biologic agents as first and second lines of treatment. The main reason for switching was loss of efficacy (72%), followed by adverse events (11%). Patients receiving a TNF-alpha inhibitor before 2016 mostly switched to ustekinumab, whereas those switching in 2016 or after mostly switched to an IL-17 inhibitor. Patients switching from a first-line TNF-alpha inhibitor before 2016 were more likely to switch to another TNF-alpha inhibitor compared with patients switching since 2018. Patients switching from etanercept were more likely to receive another TNF-alpha inhibitor rather than another therapeutic class of bDMARD compared with patients switching from adalimumab. CONCLUSION This study described the switching patterns of biologic treatments and showed how they changed over time, due to the availability of the new biologic agents primarily IL-17 inhibitors.
Collapse
Affiliation(s)
- R. Curmin
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé PubliqueParisFrance
| | - S. Guillo
- INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP‐HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi)Sorbonne UniversitéParisFrance
| | - Y. De Rycke
- INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP‐HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi)Sorbonne UniversitéParisFrance
| | - H. Bachelez
- Dermatologie, AP‐HP Hôpital Saint LouisParisFrance,Sorbonne Paris Cité Universitaire Paris DiderotParisFrance,UMR INSERM 1163, Institut ImagineParisFrance
| | - M. Beylot‐Barry
- Dermatologie CHU Bordeaux & INSERM U 1053Bordeaux UniversityBordeauxFrance
| | | | - O. Chosidow
- Dermatologie, AP‐HP, Hôpitaux universitaires Henri Mondor, Département de Dermatologie, UPEC, INSERM, Centre d'Investigation Clinique 1430, EA 7379 EpidermEUniversité Paris‐Est Créteil, UPECCréteilFrance
| | - A. Dupuy
- DermatologieCHU PontchaillouRennesFrance
| | - P. Joly
- DermatologieCHU RouenRouenFrance
| | - D. Jullien
- Dermatologie, Hospices Civils de Lyon, Hôpital E. HerriotUniversité Lyon‐1LyonFrance
| | - M.A. Richard
- Dermatologie, EA 3279: CEReSS ‐ Health Service Research and Quality of Life Center, Timone Hospital, Assistance Publique Hôpitaux de MarseilleAix‐Marseille UniversityMarseilleFrance
| | - M. Viguier
- Dermatologie‐VénéréologieHôpital Robert DebréReimsFrance
| | - E. Sbidian
- Dermatologie, AP‐HP, Hôpitaux universitaires Henri Mondor, Département de Dermatologie, UPEC, INSERM, Centre d'Investigation Clinique 1430, EA 7379 EpidermEUniversité Paris‐Est Créteil, UPECCréteilFrance
| | - C. Paul
- DermatologieCHU and Toulouse UniversityToulouseFrance
| | - E. Mahé
- DermatologieHôpital Victor DupouyArgenteuilFrance
| | - F. Tubach
- INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP‐HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi)Sorbonne UniversitéParisFrance
| | | |
Collapse
|
6
|
Soubrier M, Viguier M, Peyrin-Biroulet L, Czernichow S. AB1457 OPALE: A PROSPECTIVE OBSERVATIONAL STUDY OF THE REAL-WORLD USE OF AN ADALIMUMAB BIOSIMILAR AND EVALUATION OF NUTRITIONAL STATUS ON THE THERAPEUTIC RESPONSE. PATIENTS NUTRITIONAL STATUS AT BASELINE. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundChronic inflammatory diseases treatment has been greatly improved since the introduction of TNF inhibitors and later, of their biosimilars. In addition, epidemiological and interventional studies suggest a pathophysiological or therapeutic role, respectively, of nutrition in Inflammatory Rheumatic Diseases (IRDs).ObjectivesThe objective of the OPALE observational study was to describe in real life the profile of patients treated with an adalimumab biosimilar and to assess the impact of nutrition on disease evolution and response to treatment.MethodsThe study planned a one-year follow-up of patients with at least three visits: inclusion, six months and one year. In this study, 754 patients treated with Fresenius-Kabi adalimumab were included: 54.4 % of patients with an IRD, 42.8 % with Inflammatory Bowel Disease (IBD) and 2.8 % patients with a psoriasis. Patients’ condition was assessed using a Clinical Global Impression of disease scale (CGI, primary end point of the study). Nutritional status was assessed through clinical data (weight, BMI (Body Mass Index), abdominal circumference) and the available biological analyses results. Screening for sarcopenia was based on a SARC-F score ≥ 4. Nutritional behavior was assessed using a diet questionnaire with a list of 48 foods divided into 6 classes (Fruits & vegetables, meat, fish & eggs, dairy products & fats, starchy foods, sweet foods and drinks). Foods voluntarily withdrawn due to illness and those avoided at acute flare-ups were recommended to be reported. This analysis aims to describe IRD patients’ nutritional status at baseline.ResultsFrom 754 included patients, 410 patients presented with an IRD (Psoriatic Arthritis (PsA), n= 80 / Rheumatoid Arthritis (RA), n=102 / SpondyloArthritis (SpA), n=228). Mean patients’ age was 47.7± 14.1 years, 56% are female, mean BMI was 26.0 ± 5.4 kg/m2. From this IRD population, 28.5% of patients have a family history of chronic inflammatory disease.Mean disease duration was of 6.4 ± 8.4 years. Concerning the previous IRD treatment, 47.4% of patients had previously been treated by methotrexate among them 58% were still receiving this treatment at inclusion. Among IRD patients recruited in OPALE study, 72.8% received Fresenius Kabi adalimumab as their first biotherapy. Most of patients were assessed on the CGI scale as markedly ill (50.7%) or moderately ill (29.9%) and 110 patients (37.3%) had a score ≥ 4 on the SARC-F questionnaire (mean age 48.9 ± 14.1 years and mean BMI 27.2 ±5.6 kg/m2).Concerning the disease history at baseline, the descriptive analysis of self-administered questionnaire shows that 68.3% of patients may have changed their nutritional behavior because of their illness, by banishing several foods (mean number: 12.7 ± 10.1). These restrictions are increased during flare-ups: 32.7% of patients removed an average of 6.0 ± 5.8 additional foods number. These changes are in part based on the patients’ own beliefs: 17% of them consider that certain foods can improve their illness, 35% of patients think they have identified the foods likely to make it worse (Table 1).Table 1.Patient-reported influence of certain foods on diseasePsARASpATOTAL IRD(n=60)(n=72)(n=177)(n=309)Patients identifying foods with negative influence21225810137.5% [24.9% - 51.5%]32.4% [21.5% - 44.8%]36.0% [28.6% - 44.0%]35.4% [29.9% - 41.3%]Patients identifying foods with positive influence912274816.4% [7.8% - 28.8%]17.6% [9.5% - 28.8%]17.2% [11.7% - 24.0%]17.1% [12.9% - 22.1%]ConclusionThese preliminary baseline data from OPALE observational study confirm the risk of decreased muscle mass in IRD. Mean BMI of patients screened for sarcopenia is higher than that of non-sarcopenic patients (respectively 27.2 ± 5.6 kg/m2 and 25.6 ± 4.8 kg/m2; p=0.02). These results plead for a systematic screening for sarcopenia in IRD patients. The risk of sarcopenia could be further aggravated by inappropriate nutritional behaviors aimed at excluding food groups, which would justify dietary education of these IRD patients.Disclosure of InterestsMartin SOUBRIER Consultant of: Fresenius Kabi, Manuelle VIGUIER Consultant of: Fresenius Kabi, Laurent Peyrin-Biroulet Consultant of: Fresenius Kabi, Sebastien Czernichow Consultant of: Fresenius Kabi
Collapse
|
7
|
Castel M, Alexandre M, Jelti L, Pham-Ledard A, Viguier M, Bédane C, Tancrède-Bohin E, Musette P, Carvalho P, Cordel N, Caux F, Joly P. Updated French guidelines for the therapeutic management of bullous pemphigoid. Ann Dermatol Venereol 2022; 149:81-91. [PMID: 34702559 DOI: 10.1016/j.annder.2021.08.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Revised: 04/19/2021] [Accepted: 08/02/2021] [Indexed: 10/20/2022]
Affiliation(s)
- M Castel
- Department of Dermatology, Rouen University Hospital, University of Normandy, 76000 Rouen, France; Institut National de la Santé et de la Recherche Médicale U1234, Centre de Référence des Maladies Bulleuses Autoimmunes, University of Normandy, 76000 Rouen, France.
| | - M Alexandre
- Department of Dermatology, University of Paris XIII, 93000 Bobigny, France
| | - L Jelti
- Department of Dermatology, Rouen University Hospital, University of Normandy, 76000 Rouen, France
| | - A Pham-Ledard
- Department of Dermatology, University of Bordeaux, 33000 Bordeaux, France
| | - M Viguier
- Department of Dermatology, University of Reims, 51100 Reims, France
| | - C Bédane
- Department of Dermatology, University of Limoges, 87000 Limoges, France
| | - E Tancrède-Bohin
- Department of Dermatology, University of Paris X, 75010 Paris, France
| | - P Musette
- Department of Dermatology, University of Paris XIII, 93000 Bobigny, France
| | - P Carvalho
- Department of Dermatology, Rouen University Hospital, University of Normandy, 76000 Rouen, France
| | - N Cordel
- Department of Dermatology and Clinical Immunology, Guadeloupe University Hospital, Point-à-Pitre, Guadeloupe; Institut National de la Santé et de la Recherche Médicale U1234, Centre de Référence des Maladies Bulleuses Autoimmunes, University of Normandy, 76000 Rouen, France
| | - F Caux
- Department of Dermatology, University of Paris XIII, 93000 Bobigny, France
| | - P Joly
- Department of Dermatology, Rouen University Hospital, University of Normandy, 76000 Rouen, France; Institut National de la Santé et de la Recherche Médicale U1234, Centre de Référence des Maladies Bulleuses Autoimmunes, University of Normandy, 76000 Rouen, France
| |
Collapse
|
8
|
Curmin R, Guillo S, De Rycke Y, Bachelez H, Beylot-Barry M, Beneton N, Olivier C, Dupuy A, Joly P, Jullien D, Richard M, Viguier M, Sbidian E, Paul C, Mahé E, Tubach F. Switchs de biothérapies chez les patients atteints de psoriasis modéré à sévère dans la cohorte française PSOBIOTEQ. Rev Epidemiol Sante Publique 2022. [DOI: 10.1016/j.respe.2022.03.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
9
|
Assan F, Husson B, Hegazy S, Seneschal J, Aubin F, Mahé E, Jullien D, Sbidian E, D'Incan M, Conrad C, Brenaut E, Girard C, Richard MA, Bachelez H, Viguier M. Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographical and clinical comparative study in a large multicentre cohort. J Eur Acad Dermatol Venereol 2022; 36:1578-1583. [PMID: 35366356 PMCID: PMC9546063 DOI: 10.1111/jdv.18127] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Accepted: 03/23/2022] [Indexed: 12/04/2022]
Abstract
Background Acral pustular disease within the pustular psoriasis/psoriasis‐like spectrum mainly includes palmoplantar pustulosis (PPP) and acrodermatitis continua of Hallopeau (ACH). Scarce data argue for a distinction between these two entities, but no study has compared the clinical and epidemiologic characteristics of ACH and PPP. Objectives We aimed to perform a comparative description of the epidemiological and clinical characteristics of PPP and ACH in a multicentre retrospective cohort. Methods In this multicentre national retrospective cohort study, we compared the epidemiological characteristics, comorbidities and psoriasis characteristics of patients with PPP and ACH. Results A total of 234 patients were included: 203 (87%) with PPP, 18 (8%) with ACH and 13 (6%) with both, according to 2017 ERASPEN criteria. As compared with ACH, PPP was associated with female sex, smoking activity and higher median BMI (P = 0.01, P = 0.02 and P = 0.05 respectively). A family background of psoriasis was more frequent in PPP than ACH. Age of onset of palmoplantar disease was similar between PPP and ACH patients, median age 44 and 48 years respectively. Peripheral joint inflammatory involvement was the only rheumatic disease associated with ACH. The association with another psoriasis type was similar in PPP and ACH (57.6% and 61.1% respectively). Conclusion Our study confirms in a large PPP cohort the predominance of females and a high prevalence of smoking and elevated body mass index but also shows an association of these features in PPP as compared with ACH. In addition, it highlights peripheral arthritis as the only arthritis endotype associated with ACH. Increased knowledge of the immunogenetic backgrounds underlying these two entities is warranted to better stratify pustular psoriasis or psoriasis‐like entities for precision medicine.
Collapse
Affiliation(s)
- F Assan
- Dermatology Department, Hôpital Robert-Debré, Reims, France
| | - B Husson
- Dermatology Department, Hôpital Robert-Debré, Reims, France
| | - S Hegazy
- Dermatology Department, Hôpital Larrey, Toulouse, France
| | - J Seneschal
- Dermatology Department, National Reference Center for Rare Skin Diseases, Hôpital Saint-André, Bordeaux, France
| | - F Aubin
- Dermatology Department and Inserm 1098, Centre Hospitalo-Universitaire (CHU), Besançon, France
| | - E Mahé
- Dermatology Department, Centre Hospitalier (CH), Argenteuil, France
| | - D Jullien
- Clinical Immunology Department, CH Lyon-Sud, Lyon, France
| | - E Sbidian
- Dermatology Department, Hôpital Henri-Mondor, Créteil, France
| | - M D'Incan
- Dermatology Department, CHU Estaing, Clermont-Ferrand, France
| | - C Conrad
- Dermatology Department, Lausanne University Hospital, CHUV, Lausanne, Switzerland
| | - E Brenaut
- Dermatology Department, CHU, Brest, France
| | - C Girard
- Dermatology Department, CHU Lapeyronie, Montpellier, France
| | - M A Richard
- Dermatology Department, CEReSS-EA 3279, Research Center in Health Services and Quality of Life Aix Marseille University, University Hospital Timone, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - H Bachelez
- Université de Paris, Paris, France.,Dermatology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.,Laboratory of Genetics of Skin Diseases, INSERM UMR1163, Institut Imagine, Necker Hospital, Paris, France
| | - M Viguier
- Dermatology Department, Hôpital Robert-Debré, Reims, France
| | | |
Collapse
|
10
|
Peyrin-Biroulet L, Soubrier M, Viguier M, Czernichow S. Étude observationnelle évaluant l’état nutritionnel de patients atteints d’une maladie inflammatoire chronique et traités par un biosimilaire de l’adalimumab. NUTR CLIN METAB 2022. [DOI: 10.1016/j.nupar.2021.12.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Marniquet ME, Seneschal J, Darrigade AS, Staumont-Sallé D, Jachiet M, Nosbaum A, Tauber M, Abasq C, Ferrier Le Bouedec MC, Droitcourt C, Aubert H, Bernier C, Soria A, Raison-Peyron N, Tétart F, Aubin F, Viguier M, Valois A, Kupfer-Bessaguet I, Goronflot T, Barbarot S. Reasons for Discontinuation of dupilumab in Adult Atopic Dermatitis in Clinical Practice. Br J Dermatol 2021; 186:733-735. [PMID: 34748654 DOI: 10.1111/bjd.20883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Revised: 11/01/2021] [Accepted: 11/07/2021] [Indexed: 11/28/2022]
Abstract
Dupilumab, an anti-IL-4ɑ monoclonal antibody, has shown a positive benefit-risk ratio when treating moderate to severe atopic dermatitis (AD) in clinical studies (1). High persistence on dupilumab has recently been reported in clinical-practice setting with 77% of patients remaining in treatment for 12 months in a retrospective study including 1,963 patients with AD but reasons for discontinuation were not investigated (2).
Collapse
Affiliation(s)
| | - J Seneschal
- Dermatologie, Department of Dermatology and Paediatric Dermatology, National Reference Centre for Rare Skin disorders, Univ. Bordeaux, INSERM, BMGIC, U1035, F-33000, Bordeaux, France
| | - A-S Darrigade
- Dermatologie, Department of Dermatology and Paediatric Dermatology, National Reference Centre for Rare Skin disorders, Univ. Bordeaux, INSERM, BMGIC, U1035, F-33000, Bordeaux, France
| | | | - M Jachiet
- Dermatologie, Université de Paris, AP-HP, Service de dermatologie, Hôpital Saint-Louis, F-75010, Paris, France
| | - A Nosbaum
- Dermatologie, Hospices Civils de Lyon, Service d'Allergologie et Immunologie clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - M Tauber
- Dermatologie, CHU de Toulouse, Toulouse, France
| | - C Abasq
- Dermatologie, CHU de Brest, Brest, France
| | | | | | - H Aubert
- Dermatologie, CHU de Nantes, Nantes, France
| | - C Bernier
- Dermatologie, CHU de Nantes, Nantes, France
| | - A Soria
- Sorbonne Université, service de Dermatologie et d'Allergologie, Hôpital Tenon, APHP, Paris, France
| | | | - F Tétart
- Dermatologie, CHU de Rouen, Rouen, France
| | - F Aubin
- Dermatologie, CHU de Besançon, Besançon, France
| | - M Viguier
- Dermatologie, Hôpital Robert Debré, CHU de Reims, Reims, France
| | - A Valois
- Dermatologie, Hôpital d'instruction des Armées Sainte Anne, Toulon, France
| | | | - T Goronflot
- Epidemiologie et Biostatistique, CHU de Nantes, Nantes, France
| | - S Barbarot
- Dermatologie, CHU de Nantes, Nantes, France
| | | |
Collapse
|
12
|
Beylot-Barry M, Seneschal J, Tran D, Bachelez H, Beneton N, Dupuy A, Joly P, Jullien D, Mahé E, Paul C, Richard MA, Sbidian E, Viguier M, Chosidow O, Tubach F. Characteristics of patients with psoriasis with Psoriasis Area and Severity Index < 10 treated with biological agents: results from the French PsoBioTeq cohort. Br J Dermatol 2021; 185:1052-1054. [PMID: 34128543 DOI: 10.1111/bjd.20585] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Revised: 06/13/2021] [Accepted: 06/13/2021] [Indexed: 01/20/2023]
Affiliation(s)
- M Beylot-Barry
- Dermatology Department, Bordeaux University Hospital, Bordeaux, France
| | - J Seneschal
- Dermatology Department, Bordeaux University Hospital, Bordeaux, France
| | - D Tran
- INSERM, Pierre Louis Institute for Epidemiology and Public Health, AP-HP, Paris, France.,Sorbonne University, Pitié Salpêtrière Hospitals, Public Health Department, Pharmacoepidemiology Centre, CIC-1422, Paris, France
| | - H Bachelez
- Dermatology Department, Saint-Louis Hospital, AP-HP, Université de Paris, Paris, France
| | - N Beneton
- Dermatology Department, Le Mans Hospital, Le Mans, France
| | - A Dupuy
- Dermatology Department, Rennes University Hospital, Rennes, France
| | - P Joly
- Dermatology Department, Rouen University Hospital, Rouen, France
| | - D Jullien
- Dermatology Department, Edouard Herriot Hospital, Lyon, France
| | - E Mahé
- Dermatology Department, Victor Dupouy Hospital, Argenteuil, France
| | - C Paul
- Dermatology Department, Toulouse University and University Hospital, Toulouse, France
| | - M-A Richard
- Dermatology Department, Marseille University Hospital, Marseille, France
| | - E Sbidian
- Dermatology Department, AP-HP, Henri Mondor University Hospitals, Paris-Est Créteil University, INSERM CIC1430, Créteil, France.,EpiDermE EA7379, Créteil, France
| | - M Viguier
- Dermatology-Venereology Department, Reims University Hospital, Reims, France
| | - O Chosidow
- Dermatology Department, AP-HP, Henri Mondor University Hospitals, Paris-Est Créteil University, INSERM CIC1430, Créteil, France.,Research Group Dynamic, EA7380, Créteil Health Faculty, Alfort National Veterinary School, USC ANSES, Paris-Est Créteil University, Créteil, France
| | - F Tubach
- INSERM, Pierre Louis Institute for Epidemiology and Public Health, AP-HP, Paris, France.,Sorbonne University, Pitié Salpêtrière Hospitals, Public Health Department, Pharmacoepidemiology Centre, CIC-1422, Paris, France
| |
Collapse
|
13
|
Juzot C, Sibaud V, Amatore F, Mansard S, Seta V, Jeudy G, Pham-Ledard A, Benzaquen M, Peuvrel L, Le Corre Y, Lesage C, Viguier M, Baroudjian B, Dréno B, Quéreux G. Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study. J Eur Acad Dermatol Venereol 2021; 35:e511-e514. [PMID: 33783881 DOI: 10.1111/jdv.17253] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- C Juzot
- Department of Dermatology, Nantes University Hospital, Nantes, France
| | - V Sibaud
- Oncodermatology, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France
| | - F Amatore
- Department of dermatology, Timone Hospital, Aix-Marseille University, Marseille, France
| | - S Mansard
- Department of Dermatology, University Hospital Estaing, Clermont Ferrand, France
| | - V Seta
- Department of Dermatology, Cochin University Hospital, Paris, France
| | - G Jeudy
- Department of Dermatology, Dijon University Hospital, Dijon, France
| | - A Pham-Ledard
- Inserm U1053, Department of Dermatology, Bordeaux University Hospital, University of Bordeaux, Bordeaux, France
| | - M Benzaquen
- Department of Dermatology, Hôpital Nord, Aix-Marseille University, Marseille, France
| | - L Peuvrel
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France
| | - Y Le Corre
- Department of Dermatology, Angers University Hospital, Angers, France
| | - C Lesage
- Department of Dermatology, Montpellier University Hospital, Montpellier, France
| | - M Viguier
- Department of Dermatology, Robert Debré University Hospital, Reims University, Reims, France
| | - B Baroudjian
- Department of Dermatology, Saint-Louis University Hospital, Paris, France
| | - B Dréno
- Department of Dermatology, CIC 1413, CRCINA, Nantes University Hospital, Nantes, France
| | - G Quéreux
- Department of Dermatology, CIC 1413, CRCINA, Nantes University Hospital, Nantes, France
| |
Collapse
|
14
|
Destoop JA, Vanhaecke C, Banisadr F, Plenier Y, Viguier M, Hentzien M. Impact des recommandations HAS 2019 sur la durée de l’antibiothérapie des dermo-hypodermites bactériennes non nécrosantes chez l’adulte. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
15
|
Canard C, Molitor A, Gusdorf L, Vanhaecke C, Servettaz A, Georgin-Lavialle S, Durlach A, Touitou I, Sarrabay G, Carapito R, Barham S, Viguier M. Péri-artérite noueuse familiale non liée à un déficit en adénosine déaminase-2. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
16
|
Villani A, Amatore F, Tauber M, Guillot B, Viguier M, Beylot-Barry M, Jullien D. Impact des recommandations françaises sur les habitudes de prescription des traitements systémiques pour le psoriasis modéré à sévère. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Colas M, Vanhaecke C, Courtieu C, Lambert D, Lihoreau T, Merle C, Guerre-Schmidt A, Ginet-Mermet I, Viguier M, Pelletier F, Aubin F. Étude observationnelle sur l’impact de la prophylaxie pré-exposition de l’infection par le VIH (PrEP) sur les infections sexuellement transmissibles. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
18
|
Condamina M, Tran VT, Penso L, Hotz C, Guillem P, Villani A, Perrot P, Bru MF, Jacquet E, Nassif A, Bachelez H, Wolkenstein P, Beylot-Barry M, Richard MA, Ravaud P, Viguier M, Sbidian E. Caractéristiques cliniques des patients atteints d’hidradénite suppurée participants à la e-cohorte ComPaRe et comparaison avec les données de la littérature. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
19
|
Juzot C, Sibaud V, Amatore F, Mansard S, Seta V, Jeudy G, Pham-Ledard A, Benzaquen M, Dinulescu M, Le Corre Y, Lesage C, Viguier M, Baroudjian B, Clerc CJ, Funck-Brentano E, Giacchero D, Mortier L, Peuvrel L, Machet L, Duvert-Lehembre S, Viarnaud A, Joachim C, Bara C, Baubion E, Bergeret B, Brunet-Possenti F, Debarbieux S, Hébert V, Konstantinou MP, Marzouki-Zerouali A, Moreau-Huguen J, Phan C, Templier I, Celerier P, Aubin F, Modiano P, Poinas A, Vibet MA, Dréno B, Quéreux G. Pemphigoïdes bulleuses associées aux anti-PD-1/PDL-1 : étude nationale de 85 cas. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.123] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
20
|
Didier K, Sobanski V, Barbe C, Robbins A, Truchetet M, Barnetche T, Hot A, Fort R, Guilpain P, Maria A, Agard C, Pennaforte J, Viguier M, Martin T, Pham B, Launay D, Servettaz A. Auto-anticorps dans la sclérodermie systémique : méta-analyse de la prévalence de 9 auto-anticorps spécifiques dans différentes régions du monde. Rev Med Interne 2020. [DOI: 10.1016/j.revmed.2020.10.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
21
|
Colas M, Vanhaecke C, Courtieu C, Lambert D, Lihoreau T, Merle C, Schmidt-Guerre AR, Ginet-Mermet I, Viguier M, Pelletier F, Aubin F. Pre-exposure prophylaxis for HIV infection and new sexually transmitted infections among men who have sex with men: real-life experience from three sexual health clinics in France. J Eur Acad Dermatol Venereol 2020; 35:e94-e96. [PMID: 32697864 DOI: 10.1111/jdv.16832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- M Colas
- Service de Dermatologie, CHU et UFR Santé, Université de Franche-Comté, Besançon, France
| | - C Vanhaecke
- Service de Dermatologie, CeGIDD, CHU, Reims, France
| | - C Courtieu
- CeGIDD - Association d'Hygi'ne Sociale de Franche-Comté, Besançon, France
| | - D Lambert
- Service de Dermatologie, CeGIDD, CHU, Reims, France
| | - T Lihoreau
- Inserm, CIC 1431, Centre d'Investigation Clinique, CHU, Besançon, France
| | - C Merle
- Service de Dermatologie, CHI de Haute-Saône, Vesoul, France
| | - A R Schmidt-Guerre
- CeGIDD - Association d'Hygi'ne Sociale de Franche-Comté, Besançon, France
| | - I Ginet-Mermet
- CeGIDD - Association d'Hygi'ne Sociale de Franche-Comté, Besançon, France
| | - M Viguier
- Service de Dermatologie, CeGIDD, CHU, Reims, France
| | - F Pelletier
- Service de Dermatologie, CHU et UFR Santé, Université de Franche-Comté, Besançon, France.,CeGIDD - Association d'Hygi'ne Sociale de Franche-Comté, Besançon, France.,INSERM UMR 1098, Université de Franche-Comté, Besançon, France
| | - F Aubin
- Service de Dermatologie, CHU et UFR Santé, Université de Franche-Comté, Besançon, France.,INSERM UMR 1098, Université de Franche-Comté, Besançon, France
| |
Collapse
|
22
|
Canard C, Diaz E, Gusdorf L, Loget J, Durlach A, Graesslin O, Cadiot G, Viguier M. [Isolated Crohn's disease of the vulva with rapid clinical response to infliximab and azathioprine]. Ann Dermatol Venereol 2020; 147:569-571. [PMID: 32505375 DOI: 10.1016/j.annder.2020.04.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Revised: 03/15/2020] [Accepted: 04/22/2020] [Indexed: 11/15/2022]
Affiliation(s)
- C Canard
- Service de dermatologie-vénérologie, hôpital Robert-Debré, avenue du Général-Koenig, 51092 Reims cedex, France
| | - E Diaz
- Service de dermatologie-vénérologie, hôpital Robert-Debré, avenue du Général-Koenig, 51092 Reims cedex, France
| | - L Gusdorf
- Service de dermatologie-vénérologie, hôpital Robert-Debré, avenue du Général-Koenig, 51092 Reims cedex, France
| | - J Loget
- Service de dermatologie-vénérologie, hôpital Robert-Debré, avenue du Général-Koenig, 51092 Reims cedex, France
| | - A Durlach
- Service de biopathologie, hôpital Maison-Blanche, 51092 Reims, France
| | - O Graesslin
- Service de gynécologie obstétrique, hôpital Maison-Blanche, 51092 Reims, France
| | - G Cadiot
- Service d'hépato-gastroentérologie et de cancérologie digestive, hôpital Robert-Debré, 51092 Reims, France
| | - M Viguier
- Service de dermatologie-vénérologie, hôpital Robert-Debré, avenue du Général-Koenig, 51092 Reims cedex, France.
| |
Collapse
|
23
|
Villani AP, Amatore F, Tauber M, Guillot B, Viguier M, Beylot-Barry M, Jullien D. Impact of the French guidelines on the prescribing habits of systemic treatments for moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2020; 34:e747-e748. [PMID: 32396980 DOI: 10.1111/jdv.16601] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Accepted: 04/30/2020] [Indexed: 11/28/2022]
Affiliation(s)
- A P Villani
- Hospices Civils de Lyon, Service de Dermatologie de l'Hôpital Edouard Herriot, Université Claude Bernard Lyon I, Lyon, France.,Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie, Paris, France
| | - F Amatore
- Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie, Paris, France.,Service de Dermatologie, Hôpital de la Timone, Université Aix-Marseille, Marseille, France
| | - M Tauber
- Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie, Paris, France.,Service de Dermatologie et d'allergologie, Hôpital Larrey, Université de Toulouse, Toulouse, France
| | - B Guillot
- Service de Dermatologie, CHU de Montpellier, Université de Montpellier, Montpellier, France
| | - M Viguier
- Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie, Paris, France.,Service de Dermatologie, Hôpital Robert-Debré, Université de Reims- Champagne Ardenne, Reims, France
| | - M Beylot-Barry
- Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie, Paris, France.,Service de Dermatologie, Hôpital Saint-André, Université de Bordeaux, Bordeaux, France
| | - D Jullien
- Hospices Civils de Lyon, Service de Dermatologie de l'Hôpital Edouard Herriot, Université Claude Bernard Lyon I, Lyon, France.,Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie, Paris, France
| |
Collapse
|
24
|
Clapé A, Muller C, Plée J, Viguier M, Vanhaecke C, Bernard P. Feasibility and healthcare costs of superpotent topical corticosteroid therapy in bullous pemphigoid: a prospective, observational study in an academic centre in France. Br J Dermatol 2020; 183:775-776. [PMID: 32320476 DOI: 10.1111/bjd.19151] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- A Clapé
- Department of Dermatology, Reims University Hospital, Reims, France
| | - C Muller
- Laboratory of Dermatology, Faculty of Medicine of Reims, EA 7509, IFR 53, URCA, Reims, France
| | - J Plée
- Department of Dermatology, Reims University Hospital, Reims, France
| | - M Viguier
- Department of Dermatology, Reims University Hospital, Reims, France.,Laboratory of Dermatology, Faculty of Medicine of Reims, EA 7509, IFR 53, URCA, Reims, France
| | - C Vanhaecke
- Department of Dermatology, Reims University Hospital, Reims, France
| | - P Bernard
- Department of Dermatology, Reims University Hospital, Reims, France.,Laboratory of Dermatology, Faculty of Medicine of Reims, EA 7509, IFR 53, URCA, Reims, France
| |
Collapse
|
25
|
Husson B, Barbe C, Hegazy S, Seneschal J, Aubin F, Mahé E, Jullien D, Sbidian E, D'Incan M, Conrad C, Brenaut E, Girard C, Richard M, Bachelez H, Viguier M. Efficacy and safety of
TNF
blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol 2020; 34:2330-2338. [DOI: 10.1111/jdv.16265] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2019] [Accepted: 01/21/2020] [Indexed: 12/12/2022]
Affiliation(s)
- B. Husson
- Dermatology Department Hôpital Robert‐Debré Reims France
| | - C. Barbe
- Clinical Research Unit Hôpital Robert‐Debré Reims France
| | - S. Hegazy
- Dermatology Department Hôpital Larrey Toulouse France
| | - J. Seneschal
- Dermatology Department National Reference Center for Rare Skin Diseases Hôpital Saint‐André Bordeaux France
| | - F. Aubin
- Dermatology Department Centre Hospitalo‐Universitaire (CHU) Besançon France
| | - E. Mahé
- Dermatology Department Centre Hospitalier (CH) Argenteuil France
| | - D. Jullien
- Clinical Immunology Department CH Lyon‐Sud Lyon France
| | - E. Sbidian
- Dermatology Department Hôpital Henri‐Mondor Créteil France
| | - M. D'Incan
- Dermatology Department CHU Estaing Clermont‐Ferrand France
| | - C. Conrad
- Dermatology Department Lausanne University Hospital CHUV Lausanne Switzerland
| | | | - C. Girard
- Dermatology Department CHU Lapeyronie Montpellier France
| | - M.A. Richard
- Dermatology Department CEReSS‐EA 3279 Research Center in Health Services and Quality of Life Aix Marseille University Universitary Hospital Timone Assistance Publique Hôpitaux de Marseille Marseille France
| | - H. Bachelez
- Université de Paris Paris France
- Dermatology Department Assistance Publique‐Hôpitaux de Paris Hôpital Saint‐Louis Paris France
- Laboratory of Genetics of Skin Diseases INSERM UMR1163 Institut Imagine Necker Hospital Paris France
| | - M. Viguier
- Dermatology Department Hôpital Robert‐Debré Reims France
| | | |
Collapse
|
26
|
Amatore F, Villani AP, Tauber M, Guillot B, Viguier M. Erratum à « Recommandations françaises sur l’utilisation des traitements systémiques chez les patients adultes atteints de psoriasis modéré à sévère » [Ann. Dermatol. Venereol. 146 (6–7) (2019) 429–439]. Ann Dermatol Venereol 2020; 147:114-115. [DOI: 10.1016/j.annder.2019.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
27
|
Sigg N, Delaunay J, Livideanu CB, Aubin F, Bachelez H, Charles J, Dupuy A, Girard C, Goujon-Henry C, D’Incan M, Jullien D, Ly S, Maillard H, Misery L, Montaudié H, Parier J, Perrussel M, Richard MA, Seneschal J, Staumont-Salle D, Viguier M, Bénéton N. Eruptions cutanées dysimmunitaires et inflammatoires au cours d’un traitement par anti IL-17 dans le psoriasis: 47 cas. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
28
|
Diaz E, Vanhaecke C, Sanchez J, Durlach A, Gusdorf L, Viguier M. Angiomatose dermique diffuse ulcérée multifocale. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
29
|
Maincent O, Husson B, Kieffer J, Durlach A, Cribier B, Viguier M. Prurigo pigmentosa chez une femme enceinte. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
30
|
Clapé A, Muller C, Antonicelli F, Vanhaecke C, Viguier M, Plée J, Bernard P. Enquête de pratique de la prise en charge de la pemphigoïde bulleuse : place et coût de la dermocorticothérapie forte. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Assan F, Giboin C, Viguier M, Beylot-Barry M, Dupuy A, Bénéton N, Joly P, Jullien D, Mahé E, Paul C, Richard MA, Bachelez H, Tubach F, Chosidow O, Sbidian E. Impact de l’obésité sur l’efficacité et la tolérance du premier biomédicament : analyse à partir de la cohorte nationale Psobioteq. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
32
|
Chelli C, Loget J, Vanhaecke C, Durlach A, Gagneux Lemoussu L, Soriano C, Viguier M. Vascularite cutanée sévère avec atteinte digestive développée sous sécukinumab. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
33
|
Prouteau C, Dinulescu M, Oger E, Pruvost-Balland C, Buche S, Cogrel O, Delage M, Maruani A, Nicol I, Sbidian E, Villani A, Viguier M, Chastagner M, Grodner C, Kaoutar J, Laurent C, Leducq S, Dupuy A, Droitcourt C. Concordance de scores d’activité évalués sur photographies dans l’hidradénite suppurée. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
34
|
Masson Regnault M, Castañeda-Sanabria J, Diep Tran MHT, Beylot-Barry M, Bachelez H, Beneton N, Chosidow O, Dupuy A, Joly P, Jullien D, Mahé E, Richard MA, Viguier M, Tubach F, Sbidian E, Paul C. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ. J Eur Acad Dermatol Venereol 2019; 34:293-300. [PMID: 31419355 DOI: 10.1111/jdv.15878] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2019] [Accepted: 07/17/2019] [Indexed: 01/10/2023]
Abstract
BACKGROUND Numerous inclusion and exclusion criteria are involved in phase III moderate to severe psoriasis trials investigating the safety and efficacy of biologics. This questions the generalization of results. METHODS In this cohort study, we applied inclusion/exclusion criteria for phase III trials from original protocols (adalimumab - REVEAL, ustekinumab - PHOENIX, brodalumab - AMAGINE, secukinumab FIXTURE) to all patients enrolled in the PsoBioTeq prospective registry who received a biological agent for the first time between July 2012 and November 2017. We then compared the efficacy, drug survival and occurrence of adverse events between patients who satisfied/did not satisfy the eligibility criteria for these phase III trials. RESULTS A total of 1267 patients were enrolled, of whom 993 (78.4%) were not eligible for at least one RCT (randomized controlled trial) and 251 (19.1%) did not meet the PASI/PGA severity requirements. Apart from disease severity, the most frequent criteria resulting in exclusion were as follows: non-plaque psoriasis (12.6%), significant cardiac disease (8.4%), significant liver disease (7.3%), elevated liver enzymes (4.9-9.6%) and personal history of diabetes (9.2%). There was no difference in drug survival between the two groups. The incidence ratio of adverse events was significantly lower in eligible versus non-eligible patients [0.78 (95% CI 0.62-0.97) (P = 0.03)]. CONCLUSION The majority of patients treated with biologics in the PsoBioTeq real-life registry would not have been eligible for phase III moderate to severe psoriasis trials. Patients not eligible for psoriasis phase III clinical trials have a higher incidence of adverse events.
Collapse
Affiliation(s)
| | | | - M H T Diep Tran
- Centre de Pharmaco-épidémiologie, Pitié Salpêtrière, Paris, France
| | | | - H Bachelez
- Service de Dermatologie, AP-HP Hopital Saint Louis, Paris, France.,Sorbonne Paris Cité Université Paris Diderot, Paris, France.,UMR INSERM 1163, Institut Imagine, Paris, France
| | - N Beneton
- Dermatologie, CHU Le Mans, Le Mans, France
| | - O Chosidow
- Dermatologie, AP-HP, Hôpitaux universitaires Henri Mondor, Département de Dermatologie, UPEC, INSERM, Centre d'Investigation Clinique 1430, EA 7379 EpidermE, Université Paris-Est Créteil, UPEC, Créteil, France
| | - A Dupuy
- Dermatologie, CHU Rennes, Rennes, France
| | - P Joly
- Dermatologie, CHU Rouen, Rouen, France
| | - D Jullien
- Dermatologie, CHU Lyon, Lyon, France
| | - E Mahé
- Dermatologie, CH Argenteuil, Argenteuil, France
| | - M-A Richard
- Dermatology Department, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Timone Hospital, Assistance Publique Hôpitaux de Marseille, Aix-Marseille University, Marseille, France
| | - M Viguier
- Dermatologie-Vénéréologie, Hôpital Robert Debré, Reims, France
| | - F Tubach
- Centre de Pharmaco-épidémiologie, Pitié Salpêtrière, Paris, France.,Sorbonne Université, INSERM UMR-S 1136, Paris, France
| | - E Sbidian
- Dermatologie, AP-HP, Hôpitaux universitaires Henri Mondor, Département de Dermatologie, UPEC, INSERM, Centre d'Investigation Clinique 1430, EA 7379 EpidermE, Université Paris-Est Créteil, UPEC, Créteil, France
| | - C Paul
- Dermatologie, CHU Toulouse, Toulouse, France
| | | |
Collapse
|
35
|
Stien S, Loget J, Soibinet P, Durlach A, Fleury C, Viguier M. [Ovarian cancer revealed by mammary skin metastases and cutaneous lymphangitis]. Ann Dermatol Venereol 2019; 146:663-665. [PMID: 31522828 DOI: 10.1016/j.annder.2019.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2019] [Revised: 03/15/2019] [Accepted: 08/05/2019] [Indexed: 11/26/2022]
Affiliation(s)
- S Stien
- Service de dermatologie-vénéréologie, université Reims-Champagne-Ardenne, hôpital Robert-Debré, 51100 Reims, France
| | - J Loget
- Service de dermatologie-vénéréologie, université Reims-Champagne-Ardenne, hôpital Robert-Debré, 51100 Reims, France
| | - P Soibinet
- Service d'oncologie, institut Jean-Godinot, 51100 Reims, France
| | - A Durlach
- Service d'anatomopathologie, université Reims-Champagne-Ardenne, hôpital Maison Blanche, 51100 Reims, France
| | - C Fleury
- Service d'anatomopathologie, institut Jean-Godinot, 51100 Reims, France
| | - M Viguier
- Service de dermatologie-vénéréologie, université Reims-Champagne-Ardenne, hôpital Robert-Debré, 51100 Reims, France.
| |
Collapse
|
36
|
Prouteau C, Dinulescu M, Oger E, Pruvost-Balland C, Buche S, Cogrel O, Delage M, Maruani A, Nicol I, Sbidian E, Villani AP, Viguier M, Chastagner M, Grodner C, Kaoutar J, Laurent C, Leducq S, Dupuy A, Droitcourt C. Concordance of severity scores for photographic assessment of hidradenitis suppurativa. Br J Dermatol 2019; 182:515-516. [PMID: 31494929 DOI: 10.1111/bjd.18480] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- C Prouteau
- Department of Dermatology, CHU Rennes, F35000, Rennes, France.,University of Rennes, F35000, Rennes, France
| | - M Dinulescu
- Department of Dermatology, CHU Rennes, F35000, Rennes, France
| | - E Oger
- EA 7449 REPERES Pharmacoepidemiology and Health Services Research, F35000, Rennes, France.,Pharmacovigilance, Pharmacoepidemiology and Drug Information Departments, PEPS Research Consortium, F35000, Rennes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | - C Laurent
- Department of Dermatology, CHU Rennes, F35000, Rennes, France.,University of Rennes, F35000, Rennes, France
| | | | - A Dupuy
- Department of Dermatology, CHU Rennes, F35000, Rennes, France.,University of Rennes, F35000, Rennes, France.,EA 7449 REPERES Pharmacoepidemiology and Health Services Research, F35000, Rennes, France
| | - C Droitcourt
- Department of Dermatology, CHU Rennes, F35000, Rennes, France.,University of Rennes, F35000, Rennes, France.,EA 7449 REPERES Pharmacoepidemiology and Health Services Research, F35000, Rennes, France.,Pharmacovigilance, Pharmacoepidemiology and Drug Information Departments, PEPS Research Consortium, F35000, Rennes, France
| | | |
Collapse
|
37
|
Maho-Vaillant M, Pérals C, Golinski M, Hébert V, Riou G, Boyer O, Viguier M, Calbo S, Fazilleau N, Joly P. 018 Evolution of autoreactive B and T cells in pemphigus patients with Rituximab or corticosteroida regimen treatment. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
38
|
Sbidian E, Madrange M, Viguier M, Salmona M, Duchatelet S, Hovnanian A, Smahi A, Le Goff J, Bachelez H. Respiratory virus infection triggers acute psoriasis flares across different clinical subtypes and genetic backgrounds. Br J Dermatol 2019; 181:1304-1306. [PMID: 31150103 PMCID: PMC7161746 DOI: 10.1111/bjd.18203] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- E Sbidian
- AP-HP, Hôpitaux Universitaires Henri Mondor, Département de Dermatologie, UPEC, Créteil, F-94010, France.,Inserm, Centre d'Investigation Clinique 1430, Créteil, F-94010, France.,EA 7379 EpidermE, Université Paris-Est Créteil, UPEC, Créteil, F-94010, France
| | - M Madrange
- Laboratoire de Génétique des Maladies Autoinflammatoires, INSERM UMR 1163, Institut Imagine, Hôpital Necker, Paris, France
| | - M Viguier
- Université Reims-Champagne Ardenne, Service de Dermatologie-Vénéréologie, Hôpital Robert Debré, Reims, France
| | - M Salmona
- Sorbonne Paris Cité Université Paris Diderot, Paris, France.,Department of Virology, AP-HP, Hôpital Saint-Louis, Paris, F-75010, France.,Inserm INSIGHT U976, AP-HP, Hôpital Saint-Louis, Paris, F-75010, France
| | - S Duchatelet
- Laboratoire de Génétique des Maladies Cutanées, INSERM UMR 1163, Institut Imagine, Hôpital Necker, Paris, France
| | - A Hovnanian
- Laboratoire de Génétique des Maladies Cutanées, INSERM UMR 1163, Institut Imagine, Hôpital Necker, Paris, France
| | - A Smahi
- Laboratoire de Génétique des Maladies Autoinflammatoires, INSERM UMR 1163, Institut Imagine, Hôpital Necker, Paris, France
| | - J Le Goff
- Sorbonne Paris Cité Université Paris Diderot, Paris, France.,Department of Virology, AP-HP, Hôpital Saint-Louis, Paris, F-75010, France.,Inserm INSIGHT U976, AP-HP, Hôpital Saint-Louis, Paris, F-75010, France
| | - H Bachelez
- Laboratoire de Génétique des Maladies Autoinflammatoires, INSERM UMR 1163, Institut Imagine, Hôpital Necker, Paris, France.,Laboratoire de Génétique des Maladies Cutanées, INSERM UMR 1163, Institut Imagine, Hôpital Necker, Paris, France.,Department of Dermatology, AP-HP, Hôpital Saint-Louis, 1, avenue Claude Vellefaux., 75475, Paris cedex 10, France
| |
Collapse
|
39
|
Jachiet M, Nosbaum A, Staumont-Sallé D, Seneschal J, Viguier M, Soria A, Barbaud A, Carriou AC, Chuffart-Delplanque M, Darrigade AS, Fite C, de Masson A, Bagot M, Chevret S, Bouaziz JD. Low cardiovascular risk and poor quality of life associated with tobacco use and skin infections in adult atopic dermatitis: result of a French multicenter study. J Eur Acad Dermatol Venereol 2019; 33:e451-e453. [PMID: 31273834 DOI: 10.1111/jdv.15774] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- M Jachiet
- Service de Dermatologie et Vénérologie, Hôpital Saint Louis, AP-HP, Paris, France
| | - A Nosbaum
- Service D'allergologie et Immunologie Clinique, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - D Staumont-Sallé
- Service de Dermatologie et vénérologie, CHU Lille, Lille, France.,Inserm U995 - LIRIC - Lille Inflammation Research International Center, Univ. Lille, Lille, France
| | - J Seneschal
- Service de Dermatologie et Dermatologie Pédiatrique, Centre de Référence des maladies rares de la peau, Hôpital saint André, CHU de Bordeaux, Bordeaux, France
| | - M Viguier
- Service de Dermatologie et Vénérologie, Hôpital Robert Debré, CHU de Reims, Reims, France
| | - A Soria
- INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, AP-HP, Paris, France.,Department of Dermatology and Allergology, Tenon Hospital, Paris, France
| | - A Barbaud
- INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, AP-HP, Paris, France.,Department of Dermatology and Allergology, Tenon Hospital, Paris, France
| | - A-C Carriou
- Service de Dermatologie et vénérologie, CHU de Rennes, Reims, France
| | - M Chuffart-Delplanque
- Service de Dermatologie et vénérologie, CHU Lille, Lille, France.,Inserm U995 - LIRIC - Lille Inflammation Research International Center, Univ. Lille, Lille, France
| | - A-S Darrigade
- Service de Dermatologie et Dermatologie Pédiatrique, Centre de Référence des maladies rares de la peau, Hôpital saint André, CHU de Bordeaux, Bordeaux, France
| | - C Fite
- Service de Dermatologie, Groupe Hospitalier Paris-Saint-Joseph, Paris, France
| | - A de Masson
- Service de Dermatologie et Vénérologie, Hôpital Saint Louis, AP-HP, Paris, France
| | - M Bagot
- Service de Dermatologie et Vénérologie, Hôpital Saint Louis, AP-HP, Paris, France
| | - S Chevret
- Service de Biostatistique et Information Médicale, UMR1153, equipe ECSTRRA, Inserm, Université Paris Diderot, Paris, France
| | - J-D Bouaziz
- Service de Dermatologie et Vénérologie, Hôpital Saint Louis, AP-HP, Paris, France
| | | |
Collapse
|
40
|
Amatore F, Villani AP, Tauber M, Guillot B, Viguier M. Recommandations françaises sur l’utilisation des traitements systémiques chez les patients adultes atteints de psoriasis modéré à sévère. Ann Dermatol Venereol 2019; 146:429-439. [DOI: 10.1016/j.annder.2019.03.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
41
|
Viguier M, Aubin F, Bachelez H, Beylot-Barry M, Richard MA. Éditorial. Ann Dermatol Venereol 2019; 146:423-425. [DOI: 10.1016/j.annder.2019.04.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
42
|
Viguier M. Biosimilaires des anti-TNF dans le traitement du psoriasis. Ann Dermatol Venereol 2019; 146:492-496. [DOI: 10.1016/j.annder.2019.04.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
43
|
Affiliation(s)
- O Maincent
- Service de dermatologie-vénéréologie, hôpital Robert-Debré, avenue du Général-Koenig, 51092 Reims cedex, France
| | - B Husson
- Service de dermatologie-vénéréologie, hôpital Robert-Debré, avenue du Général-Koenig, 51092 Reims cedex, France
| | - J Kieffer
- Service de dermatologie-vénéréologie, hôpital Robert-Debré, avenue du Général-Koenig, 51092 Reims cedex, France
| | - A Durlach
- Service d'anatomo-pathologie, hôpital Maison-Blanche, 51092 Reims, France
| | - B Cribier
- Service de dermatologie, CHRU de Strasbourg, 67091 Strasbourg, France
| | - M Viguier
- Service de dermatologie-vénéréologie, hôpital Robert-Debré, avenue du Général-Koenig, 51092 Reims cedex, France.
| |
Collapse
|
44
|
Amatore F, Villani AP, Tauber M, Viguier M, Guillot B. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol 2019; 33:464-483. [PMID: 30793796 PMCID: PMC6593704 DOI: 10.1111/jdv.15340] [Citation(s) in RCA: 103] [Impact Index Per Article: 20.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2018] [Accepted: 10/12/2018] [Indexed: 12/18/2022]
Abstract
These guidelines were developed by the psoriasis research group of the French Society of Dermatology with the aim of providing updated decision‐making algorithms for the systemic treatment of adult patients with moderate‐to‐severe psoriasis. Our algorithms were generated after rigorous evaluation of existing guidelines on the treatment of psoriasis and of publications concerning new systemic treatments, not yet incorporated into existing guidelines. A total of nine existing guidelines and 53 publications related to new systemic treatments were found to meet our criteria for use in the generation of the algorithms. We have proposed two new algorithms to assess therapeutic responses, both of which incorporate emerging criteria for evaluating treatment goals. Updated therapeutic strategy algorithms, incorporating both established and new systemic therapies, were also generated for the treatment of plaque psoriasis and psoriatic arthritis, together with recommendations for the treatment of particular forms of psoriasis and treatment of patients with comorbidities.
Collapse
Affiliation(s)
- F Amatore
- Dermatology Department, Timone Hospital, Aix-Marseille University, Marseille, France
| | - A-P Villani
- Dermatology Department, Edouard Herriot Hospital, Lyon University, Lyon, France
| | - M Tauber
- Dermatology and Allergology Department, Larrey Hospital, Toulouse University, Toulouse, France
| | - M Viguier
- Dermatology Department, Robert Debré Hospital, Reims University, Reims, France.,Centre de Preuves en Dermatologie, Paris, France
| | - B Guillot
- Centre de Preuves en Dermatologie, Paris, France.,Dermatology Department, CHU of Montpellier, Montpellier University, Montpellier, France
| | | |
Collapse
|
45
|
Sanchez J, Durlach A, Bernard P, Cribier B, Viguier M. Prurigo pigmentosa in a fair-skinned European woman: Dramatic improvement with doxycycline. Ann Dermatol Venereol 2019; 146:219-222. [PMID: 30777290 DOI: 10.1016/j.annder.2018.12.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2018] [Revised: 07/30/2018] [Accepted: 12/03/2018] [Indexed: 11/17/2022]
Abstract
INTRODUCTION Prurigo pigmentosa is a rare inflammatory, pruriginous skin disease seen predominantly in young Asian women, with average age of onset in the mid-20s. OBSERVATION A 25-year-old fair-skinned European woman presented with a two-year history of pruriginous skin lesions recurring fortnightly. The initial lesions were inflammatory papules, which first emerged on the back of the neck before spreading to the shoulders, below the breasts and the back. The papules resolved leaving a reticular hyperpigmented network that gradually worsened after each episode. The clinical presentation and histopathological findings were consistent with a diagnosis of prurigo pigmentosa. Doxycycline 200mg/day was initiated, with rapid resolution, absence of any further flare-ups and gradual regression of the reticular pigmentation. DISCUSSION Prurigo pigmentosa is a skin disease of stereotypical presentation marked by frequent inflammatory flare-ups involving the trunk that are followed by periods of remission with residual hyperpigmentation. Herein we report a case observed in a fair-skinned French female subject. It is important that dermatologists are able to recognize it and distinguish it from other forms of pruriginous papular dermatosis, owing to the dramatic efficacy of tetracyclines in controlling the inflammatory flares and in reducing the adverse aesthetic impact of hyperpigmentation.
Collapse
Affiliation(s)
- J Sanchez
- Department of Dermatology, Hôpital Robert-Debré, avenue du Général Koenig, 51092 Reims cedex, France
| | - A Durlach
- Department of Histopathology, Hôpital Maison Blanche, 51092 Reims, France
| | - P Bernard
- Department of Dermatology, Hôpital Robert-Debré, avenue du Général Koenig, 51092 Reims cedex, France
| | - B Cribier
- Department of Dermatology, Centre Hospitalo Universitaire de Strasbourg, 67091 Strasbourg, France
| | - M Viguier
- Department of Dermatology, Hôpital Robert-Debré, avenue du Général Koenig, 51092 Reims cedex, France.
| |
Collapse
|
46
|
Clapé A, Vanhaecke C, Durlach A, Bernard P, Jouannaud C, Kpodar L, Cribier B, Viguier M. Granulome annulaire interstitiel diffus avec polyarthrite révélant un cancer du sein. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
47
|
Masson Regnault M, Castaneda Sanabria J, Tran M, Beylot-Barry M, Bachelez H, Beneton N, Chosidow O, Dupuy A, Joly P, Jullien D, Mahé E, Richard MA, Viguier M, Tubach F, Sbidian E, Paul C. Les patients de la vraie vie peuvent-ils être inclus dans les études cliniques évaluant des biologiques ? Analyse dans la cohorte PsoBioTeq. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
48
|
Amatore F, Viguier M, Beylot-Barry M, Mahé E, Staumont-Sallé D, Villani A, Picard-Gauci A, Girard C, Sbidian E, Bachelez H, Richard MA. Étude des prescriptions de biosimilaires de l’infliximab dans le psoriasis dans les services de dermatologie français. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
49
|
Jachiet M, Nosbaum A, Staumont-Sallé D, Seneschal J, Viguier M, Soria A, Barbaud A, Carriou AC, Chuffart-Delplanque M, Darrigade AS, Fite C, Demongeot C, Mahevas T, Chevret S, Bagot M, Bouaziz JD. Comorbidités associées à la dermatite atopique de l’adulte en France : étude nationale multicentrique. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
50
|
Stien S, Vanhaecke C, Durlach A, Bernard P, Battistella M, Viguier M. Granulomatose cutanée révélant un déficit immunitaire combiné avec efficacité spectaculaire de l’étanercept. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|